Aller au contenu principal
Accès ouvert déclaré 2025 article

Recommendations to Standardize the Conduct of Clinical Trials Evaluating Novel Therapies for Perianal Fistulizing Crohn’s Disease

6Citations signalées, ce qui n’est pas une note de qualité
22Institutions déclarées
10Pays d’affiliation déclarés

Rattachement africain : ca, si, it, nl, us, gb, br, es, fr, au. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

BACKGROUND & AIMS: Perianal fistulizing Crohn's disease (PFCD) is a potentially debilitating condition with few systematically evaluated treatment options. We aimed to develop expert recommendations to standardize study design and conduct of randomized controlled trials of medical therapy for patients with PFCD. METHODS: We utilized a RAND/UCLA appropriateness method to develop a framework for conducting randomized controlled trials of medical therapy in PFCD. An expert international panel of 15 gastroenterologists, radiologists, and colorectal surgeons rated the appropriateness of survey statements in 2 rounds of voting. Median scores of 1 to ≤3.5, >3.5 to <6.5 and ≥6.5 to 9 on survey statements reflected panel ratings of inappropriate, uncertain, and appropriate, respectively. RESULTS: A total of 292 statements were rated in the final survey, of which 156 (53.4%) were considered appropriate and formed the basis for recommendations. Trial eligibility should be decided based on both clinical and radiological criteria and patients should exhibit a minimum degree of clinical disease activity at screening. The primary efficacy outcome should be either a co-primary or composite endpoint of clinical and radiological assessments depending on treatment phase (induction vs maintenance), recognizing that clinical endpoints are meaningful for patients and radiological outcomes are essential to objectively capture the burden of disease. There was uncertainty regarding definition of radiological remission, but presence of a perianal fluid collection of any size was considered inconsistent with radiologic remission. CONCLUSIONS: These recommendations may help to standardize study design and conduct and foster clinical development of much needed therapies for this debilitating manifestation of Crohn's disease.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Recommendations to Standardize the Conduct of Clinical Trials Evaluating Novel Therapies for Perianal Fistulizing Crohn’s Disease
Date Crossref
01/07/2026
Éditeur
Elsevier BV
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Anorectal Disease Treatments and OutcomesHidradenitis Suppurativa and TreatmentsInflammatory Bowel Disease

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.